AR117929A1 - Compuestos de 1,2,4-triazin-3(2h)-ona - Google Patents
Compuestos de 1,2,4-triazin-3(2h)-onaInfo
- Publication number
- AR117929A1 AR117929A1 ARP200100258A ARP200100258A AR117929A1 AR 117929 A1 AR117929 A1 AR 117929A1 AR P200100258 A ARP200100258 A AR P200100258A AR P200100258 A ARP200100258 A AR P200100258A AR 117929 A1 AR117929 A1 AR 117929A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- hydrogen atom
- alkyl
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque R¹ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo-C₁₋₃ o un grupo haloalquilo-C₁₋₃; R² es un átomo de hidrógeno, o un átomo de halógeno; con la condición de que ambos, R¹ y R², no puedan ser un átomo de hidrógeno al mismo tiempo, con la excepción de que si R³ es un grupo fenilo orto-sustituido, ambos, R¹ y R², también pueden ser un átomo de hidrógeno; R³ es un grupo alquilo-C₁₋₃ que está sustituido una o más veces con un grupo seleccionado independientemente de un grupo alquilo-C₁₋₃, un grupo alcoxi-C₁₋₃, un grupo heterocicloalquilo y un grupo amino que está sustituido una o dos veces con un grupo alquilo-C₁₋₃, un grupo alquenilo-C₂₋₆, que está opcionalmente sustituido con un grupo alcoxi-C₁₋₃, un grupo cicloalquenilo-C₅₋₆, un grupo fenilo que está sustituido una o más veces con un grupo seleccionado independientemente de un átomo de halógeno, un grupo alquilo-C₁₋₃ y un grupo haloalquilo-C₁₋₃, un grupo heterocicloalquilo de 4 a 6 miembros que está sustituido una o más veces con un grupo seleccionado independientemente de un átomo de flúor, un grupo hidroxi y un grupo alquilo-C₁₋₃, un grupo de fórmula (2), un grupo de fórmula (3), un grupo de fórmula (4), un grupo heteroarilo de 5 a 10 miembros que está sustituido una o más veces con un grupo seleccionado independientemente de un grupo amino, un átomo de halógeno y un grupo haloalquilo-C₁₋₃, un grupo alcoxi-C₁₋₆ que está opcionalmente sustituido con un grupo seleccionado independientemente de un grupo haloalquilo-C₁₋₃, un grupo hidroxi, un grupo alquiloxi-C₁₋₃, un grupo cicloalquilo-C₄₋₆, un grupo heterocicloalquilo de 4 a 6 miembros, un grupo heteroarilo de 5 a 6 miembros, con la condición de que se excluya un grupo metoxi no sustituido; un grupo NR⁵R⁶, y un grupo de fórmula (5), R⁴ es un átomo de hidrógeno o un grupo alquilo-C₁₋₃; R⁵ es un átomo de hidrógeno; R⁶ se selecciona de un grupo alquilo-C₁₋₃ que está sustituido una o más veces con un grupo seleccionado de un grupo heteroarilo de 5 a 6 miembros, un grupo alcoxi-C₁₋₃, un grupo hidroxi, un grupo haloalquilo-C₁₋₃ y un grupo cicloalquilo C₄₋₆ que en sí está opcionalmente sustituido con un grupo hidroxialquilo-C₁₋₃, y un grupo cicloalquilo-C₅₋₆; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal de los mismos, o una sal de un estereoisómero, una sal de un tautómero, una sal de un N-óxido o una mezcla de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800126P | 2019-02-01 | 2019-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117929A1 true AR117929A1 (es) | 2021-09-01 |
Family
ID=69411437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100258A AR117929A1 (es) | 2019-02-01 | 2020-01-30 | Compuestos de 1,2,4-triazin-3(2h)-ona |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12427153B2 (es) |
| EP (1) | EP3917915A1 (es) |
| JP (1) | JP7582953B2 (es) |
| CN (1) | CN113348165B (es) |
| AR (1) | AR117929A1 (es) |
| AU (1) | AU2020215088A1 (es) |
| BR (1) | BR112021013345A2 (es) |
| CA (1) | CA3128293A1 (es) |
| TW (1) | TWI750573B (es) |
| WO (1) | WO2020157194A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| AR117929A1 (es) | 2019-02-01 | 2021-09-01 | Bayer Ag | Compuestos de 1,2,4-triazin-3(2h)-ona |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US4097671A (en) | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
| DE3172252D1 (en) | 1980-11-14 | 1985-10-17 | Ici Plc | Heterocyclic compounds |
| DE3263497D1 (en) | 1981-03-04 | 1985-06-20 | Ciba Geigy Ag | Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use |
| ZA827641B (en) * | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
| US4495185A (en) * | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
| US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
| JPS59196874A (ja) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | トリアジン誘導体 |
| JPS6153270A (ja) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| EP0220044B1 (en) | 1985-10-17 | 1991-01-30 | Smith Kline & French Laboratories Limited | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives |
| EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| JPH0676325B2 (ja) | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | オキサジアジン誘導体を有効成分として含有する抗血栓剤 |
| PT650480E (pt) | 1992-07-01 | 2002-03-28 | Ortho Pharma Corp | 1-arilsulfonil-3-fenil-1,4,5,6-tetrahidropiridazinas |
| JPH07291968A (ja) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | トリアジノン誘導体またはその塩類 |
| DE19929787A1 (de) | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
| CN1235589C (zh) | 2001-02-12 | 2006-01-11 | 默克专利股份公司 | 4型磷酸二酯酶抑制剂在制备治疗心肌疾病药物中的应用 |
| WO2008108602A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
| CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| JP5711724B2 (ja) * | 2009-04-15 | 2015-05-07 | リサーチ・トライアングル・インスティチュート | モノアミン再取り込み阻害剤 |
| FR2948940B1 (fr) | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2566864B1 (en) | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
| WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| US9890127B2 (en) * | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| KR101599009B1 (ko) * | 2013-03-29 | 2016-03-14 | 동아에스티 주식회사 | Cetp 억제 활성을 갖는 신규한 옥사졸리디논 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US11207320B2 (en) | 2015-08-13 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for cancer expressing PDE3A or SLFN12 |
| US10729680B2 (en) | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| UY37113A (es) | 2016-02-05 | 2017-08-31 | Dana Farber Cancer Inst Inc | Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento |
| SI3423440T1 (sl) * | 2016-03-04 | 2021-07-30 | Otsuka Pharmaceutical Co., Ltd. | 5-metil-6-fenil-4,5-dihidro-2H-piridazin-3-ON derivat za zdravljenje možganskih tumorjev |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| WO2020092998A1 (en) | 2018-11-01 | 2020-05-07 | The Broad Institute, Inc. | Identification of pde3 modulator responsive cancers |
| AR117929A1 (es) | 2019-02-01 | 2021-09-01 | Bayer Ag | Compuestos de 1,2,4-triazin-3(2h)-ona |
-
2020
- 2020-01-30 AR ARP200100258A patent/AR117929A1/es not_active Application Discontinuation
- 2020-01-30 EP EP20703003.2A patent/EP3917915A1/en active Pending
- 2020-01-30 AU AU2020215088A patent/AU2020215088A1/en not_active Abandoned
- 2020-01-30 BR BR112021013345-3A patent/BR112021013345A2/pt not_active IP Right Cessation
- 2020-01-30 WO PCT/EP2020/052287 patent/WO2020157194A1/en not_active Ceased
- 2020-01-30 JP JP2021544608A patent/JP7582953B2/ja active Active
- 2020-01-30 CN CN202080010707.4A patent/CN113348165B/zh active Active
- 2020-01-30 CA CA3128293A patent/CA3128293A1/en active Pending
- 2020-01-30 TW TW109102878A patent/TWI750573B/zh not_active IP Right Cessation
-
2021
- 2021-07-30 US US17/389,940 patent/US12427153B2/en active Active
-
2025
- 2025-01-21 US US19/033,373 patent/US20250170136A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3128293A1 (en) | 2020-08-06 |
| US20250170136A1 (en) | 2025-05-29 |
| TW202043203A (zh) | 2020-12-01 |
| BR112021013345A2 (pt) | 2021-09-14 |
| AU2020215088A1 (en) | 2021-07-22 |
| US12427153B2 (en) | 2025-09-30 |
| EP3917915A1 (en) | 2021-12-08 |
| US20210353630A1 (en) | 2021-11-18 |
| JP2022519080A (ja) | 2022-03-18 |
| CN113348165A (zh) | 2021-09-03 |
| CN113348165B (zh) | 2024-06-25 |
| JP7582953B2 (ja) | 2024-11-13 |
| TWI750573B (zh) | 2021-12-21 |
| WO2020157194A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| AR117929A1 (es) | Compuestos de 1,2,4-triazin-3(2h)-ona | |
| AR117916A1 (es) | Compuesto heterocíclico y su uso | |
| AR116628A1 (es) | Compuestos microbiocidas | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR117978A1 (es) | Inhibidores de 15-pgdh | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| ES2259113T3 (es) | Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion. | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR109180A1 (es) | Derivados de piperidina como moduladores del receptor cxcl11 / cxcl12 cxcr7 | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR112402A1 (es) | Dihidrooxadiazinonas | |
| ATE357142T1 (de) | 7-aminotriazolopyrimidine zur bekämpfung von schadpilzen | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| BR112022002674A2 (pt) | Derivado de 2-aminoquinazolinona | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR118557A1 (es) | Quelantes de hierro derivados del ácido 4-(2,4-bis(2-hidroxifenil)-1h-imidazol-1-il)benzoico | |
| AR110244A1 (es) | Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |